World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 2 October 2017
Main ID:  EUCTR2012-000653-32-DE
Date of registration: 12/04/2012
Prospective Registration: Yes
Primary sponsor: Novartis Pharma GmbH
Public title: A study to explore heart function during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis
Scientific title: A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) - START
Date of first enrolment: 27/06/2012
Target sample size:
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000653-32
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
Germany
Contacts
Name: Medizinischer Infoservice (MCC)   
Address:  Roonstr. 25 90429 Nürnberg Germany
Telephone: 00491802232300
Email: infoservice.novartis@novartis.com
Affiliation:  Novartis Pharma GmbH
Name: Medizinischer Infoservice (MCC)   
Address:  Roonstr. 25 90429 Nürnberg Germany
Telephone: 00491802232300
Email: infoservice.novartis@novartis.com
Affiliation:  Novartis Pharma GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
1. Written informed consent from patients capable of giving or withholding full informed consent must be obtained before any assessment is performed.
2. Subjects with relapsing remitting MS
3.
a. Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy.
b. Patients who were previously on 2nd line therapies. It is understood that these patients satisfied the above mentioned criteria listed under a. in the past. This also includes patients, who were previously treated with Fingolimod (regardless of whether or not they had already been treated within START study) but discontinued treatment due to medical reasons.
4. or patients with rapidly evolving severe RRMS (e.g. = 2 relapses with disease progression in one year and = 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).
5. Male or female aged 18 years or older at Screening.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 7000
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Known immunodeficiency syndrome.
2. Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).
3. Severe active infections, active chronic infections (hepatitis, tuberculosis).
4. Presence of malignancy (other than localized basal cell carcinoma of the skin).
5. Negative for varicella-zoster virus IgG antibodies at Screening
6. Patients with severe hepatic dysfunction (Child-Pugh-Class C)
7. Patients with the following cardiovascular conditions
• Patients receiving antiarrythmics class Ia (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol) or beta blockers
• Patients receiving heart rate lowering calcium channel blockers (e.g. verapamil, diltiazem or ivabradine) or other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic agents or pilocarpine).
• 2nd degree Mobitz Type II or higher degree AV block, Sick-sinus syndrome, or Sino-atrial heart block
• Significant QT prolongation (QTc>470 msec (female) or >450 msec (males))
• History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease (including angina pectoris), cerebrovascular disease, history of myocardial infarction, hypokalaemia, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea
8. Patients with calculated GFR> 30 ml/min
9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5mIU/ml).
Women of child-bearing potential defined as all women physiologically capable of becoming pregnant, UNLESS they are using a reliable method of contraception according to the label during the study and for 2 months after stopping treatment. At the discretion of the investigator, total abstinence from sexual intercourse is acceptable in cases where the age, career, lifestyle, or sexual orientation of the patient ensures the prevention of pregnancy.

Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to baseline. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

10. History of hypersensitivity to the active substance or to any other of the excipients of the study drugs.
11. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer




Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Conduction abnormalities in patients with relapsing-remitting multiple sclerosis
MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Intervention(s)

Trade Name: Gilenya
Product Name: Fingolimod
Product Code: FTY720
Pharmaceutical Form: Capsule, hard
CAS Number: 162359-56-0
Current Sponsor code: FTY720
Other descriptive name: Fingolimod Hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-

Primary Outcome(s)
Main Objective: To evaluate the incidence of patients with bradycardia (heart rate < 45 beats per min) and bradyarrhythmic ECG events during 6-hour monitoring period as measured by heart rate and second and third-degree AV blocks after treatment initiation of fingolimod 0.5 mg.
Primary end point(s): To evaluate the incidence of patients with bradycardia (heart rate < 45 beats per min) and bradyarrhythmic ECG events during 6-hour monitoring period as measured by heart rate and second and third-degree AV blocks after treatment initiation of fingolimod 0.5 mg.
Secondary Objective: • To evaluate the incidence of patients with other conduction abnormalities (such as QT prolongation, first degree AV block) after treatment initiation of fingolimod 0.5 mg.
• Investigate the occurrence of subsequent cardiac AEs and serious cardiac AEs during the study.
Timepoint(s) of evaluation of this end point: after 6 h
Secondary Outcome(s)
Secondary end point(s): • To evaluate the incidence of patients with other conduction abnormalities (such as QT prolongation, first degree AV block) after treatment initiation of fingolimod 0.5 mg.
• Investigate the occurrence of subsequent cardiac AEs and serious cardiac AEs during the study
Timepoint(s) of evaluation of this end point: after 7 days
Secondary ID(s)
CFTY720DDE17
Source(s) of Monetary Support
Novartis Pharma GmbH
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history